Construction intervention program for Symptom Clusters Related to Targeted Combined Immunotherapy in Patients with Hepatocellular Carcinoma Based on Symptom Management Theory

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500106110

Enrollment

Unknown

Registered

2025-07-17

Start date

2025-07-17

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Targeted Combined Immunotherapy in Patients with Hepatocellular Carcinoma

Interventions

Case series:NA

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Longitudinal prospective study:Patients with a pathological diagnosis of hepatocellular carcinoma;patients planned to receive immunotherapy combined with targeted therapy; aged >=18 years and aged =18 years and aged <=80 years;aware of their own condition, voluntary and able to independently complete this survey;

Exclusion criteria

Exclusion criteria: 1.Longitudinal prospective study:With metastasis or recurrence; with disturbance of consciousness or mental disorders; with severe comorbidities. 2.Qualitative research:With metastasis or recurrence; with disturbance of consciousness or mental disorders; with severe comorbidities.

Design outcomes

Primary

Measure	Time frame
MDASI-C;FACT-Hep;TSM-PLC;	—

Countries

China

Contacts

Public ContactYao Cong

Xi'an Jiaotong University Second Affiliated Hospital

1759416236@qq.com+86 135 7249 3004

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026